Genentech Announces FDA approval of Clinical Trial for Chugai’s Actemra for COVID-19 Pneumonia

TOKYO, March 24, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Genentech issued a press release on March 23 (local time) regarding the FDA approval of a clinical trial for Actemra ® , a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai, for the treatment of hospitalized patients with severe COVID-19 pneumonia. Please refer to the link below for details of the press release: Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia https://www.gene.com/media/press-releases/14843/2020-03-23/genentech-announces-fda-approval-of-clin [Note] Roche Announces the Initiation of a Clinical Study of Chugai’s Actemra for the Treatment of COVID-19 (A press release issued on March 19, 2020) https://www.chugai-pharm.co.jp/english/news/detail/20200319154500_709.html Trademarks used or mentioned in this release are protected by laws.

The release as fetched from its publisher. chugai-pharm.co.jp ↗